Cello Therapeutics, Inc.

Cello Therapeutics, Inc. (Cello) was founded in April 2016 and specializes in the development of nanoparticles for cancer treatment. Our nanoparticles are composed of FDA-approved cancer drugs loaded within a biocompatible polymer core. These nanoparticles are then coated with natural red blood cell membrane, a recent breakthrough technology in the field of nanomedicine. Appearing as red blood cells to the body, these membrane-coated nanoparticles are able to avoid evoking an immune response while circulating in the bloodstream for an extended period of time for improved drug delivery to tumor sites. With this novel approach to cancer treatment, our products offer unique performance advantages for oncological applications. Currently, the company is in the drug development and testing stage. Cello Therapeutics, Inc. licenses technology and laboratory protocols for nanoparticle development from its parent company, Arytha Biosciences, LLC. Cello also benefits from the efforts of its sibling company, Cellics Therapeutics, Inc., which specializes in developing nanoparticles for biodetoxification and the treatment of infectious diseases, and provides engineering expertise in membrane-coating technology.